BIOTRONIK Expands the Peripheral Portfolio with a New Treatment Tool for Interventions in Complex Lesions
Carnelian Support Catheter from Tokai Medical Products (T.M.P) is Now Commercially Available through BIOTRONIK in Most European Countries
BIOTRONIK launched today the Carnelian®1 Support catheter,2 designed to improve the access for treatment of tortuous and highly calcified lesions. Carnelian Support is indicated for the exchange and support of guidewires into peripheral vasculature.3
Up to 40% of patients with symptomatic peripheral artery disease present with a chronic total occlusion (CTO).4 If only a guidewire is used to cross the CTO, there is a risk it will buckle once it encounters resistance by atherosclerotic plaque, stopping it from advancing further. Carnelian Support is designed to prevent this buckling by enhancing guidewire control and allowing CTO crossing.
Carnelian Support comes in five models and has a low tip profile of 1.6 and 1.8 French. Its tungsten braided shaft and platinum marker contribute to high kink resistance and excellent radiopaque visibility. The catheter’s multi-segment shaft design provides a smooth transition from the soft distal tip allowing trackability to the stiffer proximal part that ensures additional push.
“I was impressed by the Carnelian Support and Japanese crossing technique that enable the treatment of very complex lesions, as I recently had a chance to demonstrate in live cases at CLIC 2019,” explained Dr. Marco Manzi, Policlinico Abano Terme, Italy. “The Carnelian Support catheter is the right tool to tackle the most challenging crossings even in below-the-ankle (BTA) arteries.”
1. Carnelian is a trademark or registered trademark of Tokai Medical Products, Inc.
2. BIOTRONIK is the official European distributor for Carnelian Support outside of Spain and Portugal.
3. Excluding central circulatory system and neurovasculature; indicated as per IFU: Tokai Medical Products. Tokai Microcatheter, Carnelian Support IFU. 2017/12 (Rev.4).
4. Bhatt H. et al. Crossing techniques and devices in femoropopliteal chronic total occlusion intervention. Cardiovascular Revascularization Medicine. 2017.
At BIOTRONIK, patient well-being is our top priority and has been for 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases as well as chronic pain. Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular, endovascular and neuromodulation solutions. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.